Research programme: ischaemia/reperfusion injury therapy - Medicure

Drug Profile

Research programme: ischaemia/reperfusion injury therapy - Medicure

Alternative Names: MC-5422

Latest Information Update: 02 Nov 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medicure
  • Class
  • Mechanism of Action Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Myocardial ischaemia; Reperfusion injury

Most Recent Events

  • 02 Nov 2009 Suspended - Preclinical for Myocardial ischaemia in Canada (unspecified route)
  • 02 Nov 2009 Suspended - Preclinical for Reperfusion injury in Canada (unspecified route)
  • 17 Apr 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top